"Later they can issue new shares in secondary offering and create float. "
If it works, the business plan for insiders would be to get the secondary at preferential terms to sell to retail for a profit. Retail that buys here could be decimated while insiders maintain control and retain the profits from increased market value.
Can't figure how I could benefit as a retail shareholder here. Even if the price did continue to go up. My percentage of the company would continue to be diluted. Under the Anavex ATM model current retail holders will suffer minimum dilution as capital is raised in the future.
"so no one understands this disease and claiming that NTRP drug is inferior to AVXL is unproven"
Well said! I am an ex AVXL investor. I like NTRP's chances a lot better. Management has signaled that bryostatin will succeed in the ongoing Alzheimer's trial. They are considering expanding its use in Fragile X and other indications. The low os and float will propel the stock up on any positive news while AVXL is still stuck in the mud. I see no hope for AVXL shareholders
Market Data 
Markets 
AI
